Yoshinori Hirashima
Ono, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 01, 2026
A study to learn how well the combination of encorafenib and binimetinib works and how safe it is in adults with thyroid cancer: a plain language summary.
Journal: Future oncology (London, England)
Published: March 24, 2026
Encorafenib plus binimetinib for BRAF V600-mutated thyroid cancer in Japan: final analysis.
Journal: International journal of clinical oncology
Published: March 12, 2026
Nivolumab plus chemotherapy in Asian people with advanced or recurrent stomach or gastroesophageal junction cancer (ATTRACTION-4 study): a plain language summary.
Journal: Future oncology (London, England)
Published: March 02, 2026
Health-related quality of life with encorafenib plus binimetinib for BRAF V600E thyroid cancer.
Journal: European thyroid journal
Published: September 24, 2025
A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic BRAF-Mutated Thyroid Cancer in Japan.
Journal: Thyroid : official journal of the American Thyroid Association
Published: February 12, 2024
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Journal: The lancet. Gastroenterology & hepatology
Published: December 24, 2023
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: June 09, 2021
A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial.
Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Published: November 18, 2017
A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma.
Journal: International journal of clinical oncology
Published: January 12, 2017
A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors.
Journal: Cancer chemotherapy and pharmacology
Published: January 14, 2016
Last Updated: 09/26/2026